Cellular APOBEC3A deaminase drives mutations in the SARS-CoV-2 genome

Nucleic Acids Res. 2023 Jan 25;51(2):783-795. doi: 10.1093/nar/gkac1238.

Abstract

The number of genetic variations in the SARS-CoV-2 genome has been increasing primarily due to continuous viral mutations. Here, we report that the human APOBEC3A (A3A) cytidine deaminase plays a critical role in the induction of C-to-U substitutions in the SARS-CoV-2 genome. Bioinformatic analysis of the chronological genetic changes in a sequence database indicated that the largest UC-to-UU mutation signature, consistent with APOBEC-recognized nucleotide motifs, was predominant in single-stranded RNA regions of the viral genome. In SARS-CoV-2-infected cells, exogenous expression of A3A but not expression of other APOBEC proteins induced UC-to-UU mutations in viral RNA (vRNA). Additionally, the mutated C bases were often located at the tips in bulge or loop regions in the vRNA secondary structure. Interestingly, A3A mRNA expression was drastically increased by interferons (IFNs) and tumour necrosis factor-α (TNF-α) in epithelial cells derived from the respiratory system, a site of efficient SARS-CoV-2 replication. Moreover, the UC-to-UU mutation rate was increased in SARS-CoV-2 produced from lung epithelial cells treated with IFN-ß and TNF-α, but not from CRISPR/Cas9-based A3A knockout cells. Collectively, these findings demonstrate that A3A is a primary host factor that drives mutations in the SARS-CoV-2 RNA genome via RNA editing.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • COVID-19 / metabolism
  • COVID-19 / virology
  • Cytidine Deaminase* / metabolism
  • Genome, Viral
  • Humans
  • Mutation*
  • RNA, Viral / genetics
  • SARS-CoV-2* / genetics
  • Tumor Necrosis Factor-alpha / genetics

Substances

  • APOBEC3A protein, human
  • Cytidine Deaminase
  • RNA, Viral
  • Tumor Necrosis Factor-alpha